ArticleAnnals of African medicine2026
An Interesting Case of Hereditary Hemorrhagic Telangiectasia in a Patient with Recurrent Epistaxis.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractHereditary hemorrhagic telangiectasia is a disorder of blood vessels characterized by angiogenesis and chronic dilatation. Hereby presenting a case of an elderly female presenting with recurrent epistaxis with spontaneous resolution, multiple episodes of per rectal bleed since the past 10 years, leading to chronic anaemia and required blood transfusions. Further evaluation revealed the presence of multiple nasal, gastric, and colonic telangiectasias without active bleeding and complex pulmonary arteriovenous malformations. The patient was transfused with five pints of packed cell volume, cauterization done in view of nasal telangiectasia, and started on oral form of thalidomide 50 mg once daily to prevent angiogenesis, further progression, and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.